BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 184 filers reported holding BRIDGEBIO PHARMA INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $662,784 | +55.7% | 25,134 | +1.6% | 0.01% | +100.0% |
| Q2 2023 | $425,666 | +31.7% | 24,748 | +27.0% | 0.00% | 0.0% |
| Q1 2023 | $323,161 | +125.3% | 19,491 | +3.5% | 0.00% | +200.0% |
| Q4 2022 | $143,439 | -20.3% | 18,824 | +4.2% | 0.00% | -50.0% |
| Q3 2022 | $180,000 | +10.4% | 18,061 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $163,000 | +0.6% | 18,001 | +13.1% | 0.00% | +100.0% |
| Q1 2022 | $162,000 | -46.5% | 15,915 | -12.3% | 0.00% | -50.0% |
| Q4 2021 | $303,000 | -64.7% | 18,139 | -0.9% | 0.00% | -71.4% |
| Q3 2021 | $858,000 | -22.8% | 18,299 | +0.4% | 0.01% | -22.2% |
| Q2 2021 | $1,111,000 | +18.7% | 18,221 | +19.9% | 0.01% | +12.5% |
| Q1 2021 | $936,000 | – | 15,194 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |